Relationships between biochemical markers of bone and cartilage degradation with radiological progression in patients with knee osteoarthritis receiving risedronate: the Knee Osteoarthritis Structural Arthritis randomized clinical trial

Osteoarthritis and Cartilage

Volumn 16, Issue 6, 2008, Pages 660-666

  Garnero, P ^a,b   Aronstein, W S ^c   Cohen, S B ^d   Conaghan, P G ^e   Cline, G A ^c   Christiansen, C ^f   Beary, J F ^c   Meyer, J M ^c   Bingham III, C O ^g  

^a INSERM   (France)

^b Molecular Markers   (France)

^c PROCTER AND GAMBLE PHARMACEUTICALS   (United States)

^d St Paul Medical Center   (United States)

^e UNIVERSITY OF LEEDS   (United Kingdom)

^f CENTER FOR CLINICAL AND BASIC RESEARCH   (Denmark)

^g JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

Biochemical marker; Bisphosphonate; Osteoarthritis; Type II collagen

Indexed keywords

AMINO TERMINAL TELOPEPTIDE; BIOCHEMICAL MARKER; CARBOXY TERMINAL COLLAGEN TYPE 2 TELOPEPTIDE; CARBOXY TERMINAL TELOPEPTIDE; PLACEBO; RISEDRONIC ACID;

ADULT; AGED; ARTICLE; BONE DEFECT; CARTILAGE DEGENERATION; CLINICAL TRIAL; CONFIDENCE INTERVAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE COURSE; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG MECHANISM; DRUG RESPONSE; EUROPEAN UNION; FEMALE; FOLLOW UP; HUMAN; KNEE OSTEOARTHRITIS; KNEE RADIOGRAPHY; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NORTH AMERICA; PRIORITY JOURNAL; PROTEIN URINE LEVEL; RANDOMIZED CONTROLLED TRIAL; RISK REDUCTION;

AGED; BIOLOGICAL MARKERS; BONE DENSITY CONSERVATION AGENTS; BONE RESORPTION; CARTILAGE, ARTICULAR; COLLAGEN TYPE I; DISEASE PROGRESSION; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; ETIDRONIC ACID; FEMALE; HUMANS; MALE; MIDDLE AGED; OSTEOARTHRITIS, KNEE; PEPTIDES;

EID: 44449109574     PISSN: 10634584     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.joca.2007.10.002     Document Type: Article

References (41)

1. Quam J.P., Michet Jr. C.J., Wilson M.G., Rand J.A., Ilstrup D.M., Melton III L.J., et al. Total knee arthroplasty: a population-based study. Mayo Clin Proc 66 (1991) 589-595
2. Hochberg M.C., Altman R.D., Brand K.D., Clark B.M., Dieppe P.A., Griffin M.R., et al. Guidelines for the medical management of osteoarthritis. Part II. Osteoarthritis of the knee. Arthritis Rheum 38 (1995) 1541-1546
3. Reginster J.Y., Derosy R., Rovati L.C., Lee R.L., Lejeune E., Bruyerre O., et al. Long term effects of glucosamine suphate on osteoarthritis progression: a randomized, placebo-controlled clinical trial. Lancet 357 (2001) 251-256
4. Pavelka K., Gatterova J., Olejarova M., Machacek S., Giovanelli G., and Rovati L.C. Glucosamine sulphate use and delay of progression of knee osteoarthritis: a 3 year, randomized, placebo controlled double blind study. Arch Intern Med 162 (2002) 2113-2123
5. Dougados M., Nguyen M., Berdah L., Mazières B., Vignon E., and Lequesne M. Evaluation of the structure-modifying effects of diacerein in hip osteoarthritis. Arthritis Rheum 44 (2002) 2539-2547
6. Brandt K.D., Mazzuca S.A., Katz B.P., Lane K.A., Buckwalter K.A., Yocum D.E., et al. Effects of doxycycline on progression of osteoarthritis: results of a randomized, placebo-controlled, double-blind trial. Arthritis Rheum 52 (2005) 2015-2025
7. Dieppe P., Cushnaghan J., Young P., and Kirwan J. Prediction of the progression of joint space narrowing in osteoarthritis of the knee by bone scintigraphy. Ann Rheum Dis 52 (1993) 557-563
8. Felson D.T., McLaughlin S., Goggins J., LaValley M.P., Gale M.E., Totterman S., et al. Bone marrow edema and its relation to progression of knee osteoarthritis. Ann Intern Med 139 (2003) 330-336
9. Hunter D.J., Zhang Y., Niu S., Goggins J., Amin S., LaValley M.P., et al. Increase in bone marrow lesions associated with cartilage loss: a longitudinal magnetic resonance imaging study of knee osteoarthritis. Arthritis Rheum 54 (2006) 1529-1535
10. Bettica P., Cline G., Hart D.J., Meyer J., and Spector T.D. Evidence for increased bone resorption in patients with progressive knee osteoarthritis: longitudinal results from the Chingford study. Arthritis Rheum 46 (2002) 3178-3184
11. Garnero P. Use of biochemical markers to study and follow patients with osteoarthritis. Curr Rheumatol Rep 8 (2006) 37-44
12. Poole A.R. Biochemical/immunochemical biomarkers of osteoarthritis: utility for prediction of incident or progressive osteoarthritis. Rheum Dis Clin North Am 29 (2003) 803-818
13. Garnero P., Ayral X., Rousseau J.C., Christgau S., Sandell L.J., Dougados M., et al. Uncoupling of type II collagen synthesis and degradation predicts progression of joint damage in patients with knee osteoarthritis. Arthritis Rheum 46 (2002) 2613-2624
14. Reijman M., Hazes J.M., Bierma-Zienstra M.A., Koes W., Christgau S., Christiansen C., et al. Predictive value of a cartilage degradation marker for radiologic osteoarthritis: the Rotterdam study. Arthritis Rheum 50 (2004) 2471-2478
15. Mazieres B., Garnero P., Gueguen A., Abbal M., Berdah L., Freiburghaus C., et al. Molecular markers of cartilage breakdown and synovitis are strong independent predictors of structural progression of hip osteoarthritis (OA). The ECHODIAH cohort. Ann Rheum Dis 65 (2006) 354-359
16. Lehmann H.J., Mouritzen U., Christgau S., Cloos P.A., and Christiansen C. Effect of bisphosphonates on cartilage turnover assessed with a newly developed assay for collagen type II degradation products. Ann Rheum Dis 61 (2002) 530-533
17. Spector T.D., Conaghan P.G., Buckland-Wright J.C., Garnero P., Cline G.A., Beary J.F., et al. Effect of risedronate on joint structure and symptoms of knee osteoarthritis: results of the BRISK randomized, controlled trial. Arthritis Res Ther 7 (2005) R625-R633
18. Bingham III C.O., Buckland-Wright J.C., Garnero P., Cohen S.P., Dougados M., Silvano Adami S., et al. Risedronate decreases biochemical markers of cartilage degradation but does not decrease symptoms or slow radiographic progression in patients with medial compartment osteoarthritis of the knee: results of the two-year multinational knee osteoarthritis structural arthritis study. Arthritis Rheum 54 (2006) 3494-3507
19. Altman R., Asch E., Bloch D., Bole G., Borenstein D., Brandt K., et al. Development of criteria for the classification and reporting of osteoarthritis. Classification of osteoarthritis of the knee. Diagnostic and Therapeutic Criteria Committee of the American Rheumatism Association. Arthritis Rheum 29 (1986) 1039-1049
20. Buckland-Wright J.C. Protocols for precise radio-anatomical positioning of the tibiofemoral and patellofemoral compartments of the knee. Osteoarthritis Cartilage Suppl A (1995) 71-80
21. Buckland-Wright J.C., Bird C.F., Ritter-Hrncirik C.A., Cline G.A., Tonkin C., Hangartner T.N., et al. X-ray technologists' reproducibility from automated measurements of the medial tibiofemoral joint space width in knee osteoarthritis for a multicenter, multinational clinical trial. J Rheumatol 30 (2003) 329-338
22. Hanson D.A., Weis M.A., Bollen A.M., Maslan S.L., Singer F.R., and Eyre D.R. A specific immunoassay for monitoring human bone resorption: quantitation of type I collagen cross-linked N-telopeptides in urine. J Bone Miner Res 7 (1992) 1251-1258
23. Christgau S., Garnero P., Fledelius C., Moniz C., Ensig M., Gineyts E., et al. Collagen type II C-telopeptide fragments as an index of cartilage degradation. Bone 29 (2001) 209-215
24. Hahn G.J., and Meeker W.Q. Statistical Intervals: A Guide for Practitioners (1991), John Wiley & Sons, Inc, New York (Part 5.2)
25. Mouritzen U., Christgau S., Lehman H.J., Tanko L.B., and Christiansen C. Cartilage turnover assessed with a newly developed assay measuring collagen type II degradation products: influence of age, sex, menopause, hormone replacement therapy, and body mass index. Ann Rheum Dis 62 (2003) 332-336
26. Garnero P., Sornay-Rendu E., Arlot M., Christiansen C., and Delmas P.D. Association between spine disc degeneration and type II Collagen degradation in postmenopausal women: the OFELY study. Arthritis Rheum 50 (2004) 3137-3144
27. Landewé R., Geusens P., Maarten B., Van der Heijde D., Lems W., Koppele J.T., et al. Markers for type II collagen breakdown predict the effect of disease modifying treatment on long-term radiographic progression in patients with rheumatoid arthritis. Arthritis Rheum 50 (2004) 1390-1399
28. Sondergaard B.C., Henriksen K., Wulf H., Oestergaard S., Schurigt U., Brauer R., et al. Relative contribution of matrix metalloprotease and cysteine protease activities to cytokine-stimulated articular cartilage degradation. Osteoarthritis Cartilage 4 (2006) 738-748
29. Garnero P., Christgau S., and Delmas P.D. The bisphosphonate zoledronate decreases type II collagen breakdown in patients with Paget's disease of bone. Bone 28 (2001) 461-464
30. Oestergaard S., Sondergaard B.C., Hoegh-Andersen P., Henriksen K., Qvist P., Christiansen C., et al. Effects of ovariectomy and estrogen therapy on type II collagen degradation and structural integrity of articular cartilage in rats. Arthritis Rheum 54 (2006) 2441-2451
31. Bay-Jensen A.-C., Thomas A.L., Ben-Tabassi N., Kristensen P.W., Kjaersgaard-Andersen P., Sandell L., et al. Biochemical markers of type II collagen breakdown and synthesis are positioned at specific sites in human osteoarthritic knee cartilage. Osteoarthritis Cartilage 16 (2008) 615-623
32. Meyer J F.R., and Prenger M.C. Risedronate but not alendronate slows disease progression in the guinea pig model of primary osteoarthritis. J Bone Miner Res 16 Suppl 1 (2001) SA472
33. Buckland-Wright J.C., Messent E.A., Bingham III C.O., Ward R.J., and Tonkin C. A 2 yr longitudinal radiographic study examining the effect of a bisphosphonates (risedronate) upon subchondral bone loss in osteoarthritic knee patients. Rheumatology (Oxford) 46 (2007) 257-264
34. Konttinen Y.T., Salo T., Hanemaaijer R., Valleala H., Sorsa T., Sutinen M., et al. Collagenase-3 (MMP-13) and its activator in rheumatoid arthritis: localization in the pannus-hard tissue junction and inhibition by alendronate. Matrix Biol 18 (1999) 401-412
35. Derenne S., Amiot M., Barillé S., Collette M., Robillard N., Berthaud P., et al. Zoledronate is a potent inhibitor of myeloma cell growth and secretion of Il-6 and MMP-1 by tumoral environment. J Bone Miner Res 14 (1999) 2048-2056
36. Eastell R., Barton I., Hannon R.A., Chines A., Garnero P., and Delmas P.D. Relationship of early changes in bone resorption to the reduction in fracture risk with risedronate. J Bone Miner Res 18 (2003) 1051-1056
37. Coleman R.E., Major P., Lipton A., Brown J.E., Lee K.A., Smith M., et al. Predictive value of bone resorption and formation markers in cancer patients with bone metastases receiving the bisphosphonate zoledronic acid. J Clin Oncol 23 (2005) 4925-4935
38. Cahue S., Sharma L., Dunlop D., Ionescu M., Song J., Lobanok T., et al. The ratio of type II collagen breakdown to synthesis and its relationship with the progression of knee osteoarthritis. Osteoarthritis Cartilage 15 (2007) 819-823
39. Garnero P., Charni N., Juillet F., Conrozier T., and Vignon E. Increased urinary type II collagen helical (Helix-II) and C-telopeptide (CTX-II) levels are independently associated with a rapidly destructive hip osteoarthritis. Ann Rheum Dis 65 (2006) 1639-1644
40. Deberg M.A., Labasse A.H., Collette J., Seidel L., Reginster J.Y., and Henrotin Y.E. One-year increase of Coll 2-1, a new marker of type II collagen degradation, in urine is highly predictive of radiological OA progression. Osteoarthritis Cartilage 13 (2005) 1059-1065
41. Sharif M., Kirwan J.R., Elson C.J., Granell R., and Clarke S. Suggestion of nonlinear or phasic progression of knee osteoarthritis based on measurements of serum cartilage oligomeric matrix protein levels over five years. Arthritis Rheum 50 (2004) 2479-2488